Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Biocurcumax (also known as BCM-95 or Curcugreen) is a proprietary, high-bioavailability turmeric extract developed by Arjuna Natural Extracts Ltd. It is composed of 95% curcuminoids complexed with turmeric essential oils, specifically standardized to 45% ar-turmerone, which enhances the absorption of curcumin by approximately seven-fold compared to standard extracts. Curcumin, the primary bioactive component, exerts therapeutic effects by modulating multiple signaling pathways, including the inhibition of nuclear factor-kappa B (NF-kB), cyclooxygenase-2 (COX-2), and 5-lipoxygenase (5-LOX), as well as reducing levels of pro-inflammatory cytokines like TNF-alpha and IL-6. Biocurcumax has been clinically evaluated for a variety of conditions, including rheumatoid arthritis, osteoarthritis, major depressive disorder, and as an adjunct treatment for malaria.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Biocurcumax.